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INTRODUCTION
Sedation during endoscopy is advantageous to patients for 
comfortable endoscopy without distress and to endoscopists 
for accurate and relaxed endoscopy. Conscious sedation en-
doscopy refers to the moderate level of sedation according to 
the American Society of Anesthesiologists (ASA) standard in-
duced by administering a sedative, in order to maintain a pa-
tient in a responsive state to a slight touch or sound but capa-
ble of respiration at the same time for the adequate oxygen sup-
ply and respiration. Midazolam and propofol is most common-
ly used clinically for this purpose.
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Recently, endoscopic submucosal dissection (ESD), which 
requires relatively longer, deeper and more stable sedation than 
other endoscopy, is increasing for the treatment of early gas-
tric cancer or gastric dysplasia. There are only few studies on 
the type, dose and safety of sedatives adequate for ESD. This 
study was performed to compare the sedative effect and safety 
between midazolam only and the combination of midazolam 
and propofol for sedation during the ESD.
MATERIALS AND METHODS
Patients 
This study involved patients of the ASA physical status clas-
sification I and II among early gastric cancer or gastric dys-
plasia patients scheduled to receive ESD between 1 May 2008 
and 30 May 2009 at Chungbuk National University Hospital. 
Patients who provided the informed consent and received the 
ESD were randomly assigned consecutively to either midazo-
lam only group (M group) or midazolam and propofol com-
bination group (MP group). Patients who had experienced 
side effects from premedication for sedation or medicinal po-
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isoning; patients currently using drugs that could interact with 
midazolam or propofol; patients who cannot communicate 
due to psychological problems such as dementia, schizophrenia, 
or depression, or a gravida were excluded from the study.
Preparations before the procedure
Every patient fasted for eight hours. Scopolamine 20 mg and 
pethidine HCI 50 µg were injected before the endoscopy. Sys-
tolic and diastolic blood pressure, heart rate, respiration rate, 
and oxygen saturation were measured twice each, which was 
used as the baseline at rest.
Medication dose and periprocedural care
In case of M group, midazolam 5 mg was first injected in-
travenously for sedation, which was determined by the loss 
of eyelash reflex. Midazolam 2 mg was injected again if a pa-
tient does not achieve sedation 3 minutes after the first injec-
tion, and 1mg dose was injected continuously until sedation 
was achieved. The endoscope was inserted after the sedation, 
and additional 1 mg was injected when the patient stirs or 
shows signs of discomfort during insertion or procedure. The 
maximum total dose of midazolam was 15 mg, and propopol 
was injected thereafter instead of midazolam when the patient 
moves severely.
In case of MP group, midazolam 5 mg and propofol 20 mg 
was first injected intravenously for sedation. Additional 20 mg 
of propofol was injected when the sedation is not achieved 3 
minutes later and 20 mg dose of propofol was injected re-
peatedly at 1 minute interval until sedation was achieved. The 
endoscope was inserted after the sedation, and additional 20 
mg of propofol was injected intravenously when the patient 
stirs or shows signs of discomfort during the insertion or pro-
cedure.
Oxygen 2 L/min was provided through nasal cavity during 
the procedure, and pulse oxymetry was used to monitor the sat-
uration level of oxygen.
Outcome measures
The duration of procedure was counted from the entry of 
the sedatives until the withdrawal of endoscope following 
submucosal dissection and confirmation of bleeding. Total 
dose of midazolam and propofol during the duration of pro-
cedure was measured. Safety was monitored by measuring 
systolic and diastolic blood pressure, heart rate, respiration 
rate, and oxygen saturation before and after the procedure and 
at 10 minute interval during the procedure. The patient’s re-
covery grade was also evaluated after the procedure. The re-
covery grade was measured using Aldrete score consisting of 
5 items, including activity, respiration, circulation, conscious-
ness and color with a maximum total score of 10 points (2 
points for each item). Recovery grade was evaluated by time 
from the completion of the procedure until when the Aldrete 
score reaches 10 points. Patients scored the degree of their 
pain such as pharyngolaryngeal discomfort and gag reflex on 
the visual analogue scale (VAS; 0, without discomfort; 10, most 
discomforting than any other experiences in one’s life) one 
hour before the procedure and the next day, which was con-
verted to a score system reflecting the patient’s satisfaction. Se-
dative effect was evaluated by the degree of movement, aspi-
ration rate, and the operator’s satisfaction (very satisfying, 
quite satisfying, moderately satisfying, and dissatisfying). Post-
procedure rebleeding or perforation was confirmed for the 
possibility of complications. Olympus GFS-Q260 was used for 
endoscopy, which was performed by one endoscopist. 
Statistical analysis
Variables are expressed as mean±standard deviation. One-
way ANOVA, t-test, Student’s t-test, chi-square test, and Fish-
er’s exact test were performed for statistical analysis of vari-
ables. A p-value of less than 0.05 was considered statistically sig-
nificant. SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) was 
used for statistical analysis.
RESULTS 
Patient characteristics
A total of 44 patients enrolled in this study were randomiz-
ed to either M group (n=22) or MP group (n=22). The mean 
ages of the two groups were similar as 61.1±8.5 years old and 
62.5±10.5 years old in M group and MP group, respectively 
(p=0.63). Sex ratios were also similar between the two groups 
(male:female both 18:7 in M group and MP group; p=1.00). 
ASA classification was 1.45SA cl in M group and 1.36M gro in 
MP group, without significant difference (p=0.55)(Table 1).
Duration of procedure and dose of midazolam and 
propofol
The mean duration of procedure was 49.6±19.7 minutes in 
M group and 48.6±21.5 minutes in MP group, without statis-
tically significant difference (p=0.87). The average dose of se-
datives in M group was 12.5±2.5 mg for midazolam; 10 pa-
tients (45%) among them were not sedated until the total 15 
mg of midazolam was injected and were switched to 154.0± 
122.5 mg of propofol. Every patient in MP group received mi-
dazolam 5 mg and the average total dose was 181.4±109.8 mg, 
which was not significantly different from the dose of propofol 
administered to 10 patients in M group (p=0.533)(Table 2).
Sedative effect
Sedative effect was evaluated by counting the number of mo-24  Clin Endosc 2011;44:22-26
Midazolam Plus Propofol during Endoscopy
vements, which were measured on average 12.6 times in M gr-
oup and 4.8 times in MP group. MP group patients moved sig-
nificantly less than M group (p<0.004).
Safety
The systolic blood pressures of M group and MP group be-
fore and during the procedure were 131±22 vs. 138±20 mm 
Hg and 139±27 vs. 130±33 mm Hg. Six patients each from M 
group and MP group experienced decreased blood pressure of 
more than 20 mm Hg (both 27.3%). Heart rate was changed 
from 72±14/min at baseline to 100±13/min after medication 
in M group; 79±17/min and 97±22/min each in MP group; th-
ere was no statistically significant difference in the number of 
patients with 20% or more heart rate change between M group 
(n=2; 9.1%) and MP group (n=0) (p=0.49). There was also no 
significant difference in the change of respiration rate and the 
degree of oxygen saturation. There was 1 patient at each group 
whose oxygen saturation was decreased to less than 90%, wi-
thout significant difference between the two groups. Total Al-
drete score after the procedure were similar as 14.3±6.8s and 
15.2±5.2s for M group and MP group, respectively (p=0.62)
(Table 3).
Patient and endoscopist satisfaction
Patient VAS was evaluated 1 hour before the procedure and 
the next day to measure the patient satisfaction indirectly, 
which was not significantly different between M group and MP 
group either 1 hour before the procedure (3.2±2.9 and 1.9±2.3; 
p=0.10) or 24 hours later (2.0±2.1 and 1.0±1.7; p=0.09). The 
percentage of very satisfying and quite satisfying cases by the 
endoscopist’s evaluation was significantly higher in MP group 
(100%) compared to M group (50%) (p<0.001)(Fig. 1).
Side effects
Post-procedure rebleeding occurred in 2 patients in each 
Table 1. Comparison of Baseline Characteristics between Mida-







Age, yr 61.1±8.50 62.5±10.5 0.63
Male, No. (%) 18 (82) 18 (82) 1.00
ASA grade
Grade 1 12 14 0.55
Grade 2 10 8 0.58
Total time, min 49.6±19.7 48.6±21.5 0.87
Midazolam dose, mg 12.5±2.50 5 0.05
Propofol dose, mg - 181.4±109.8 -
Convert to use of propofol
Patients, No (%) 10 (45)
Propofol dose, mg 154.0±122.5 181.4±109.8 1.00
ASA, American Society of Anesthesiologists.
Table 2. Comparison of Sedative Effects between Midazolam 







Restlessness, No. 12.6±10.9 4.8±4.0 0.004
Patient’s discomfort (VAS 0-10)
After 1 hr 3.2±2.9 1.9±2.3 0.100
After 24 hr 2.0±2.1 1.0±1.7 0.090
VAS, visual analogue scale.
Table 3. Comparison of Patient’s Safety Index between Midazolam 







↓ 20 mm Hg in BP, No. (%) 6 (27.3) 6 (27.3) 1.00
↓ 20% in PR, No. (%) 2 (9.1)0 0 (0.0)0 0.49
↓ Below 90% in SaO2 
  for ≥10 sec, No. (%)
1 (2.5)0 1 (2.5)0 1.00
Time to Aldrete score 
  of 10 points, min 
14.3±6.8 15.2±5.2 0.62
BP, blood pressure; PR, pulse rate.






Rebleeding, No. (%) 2 (9.1) 2 (9.1) 1.00
Perforation, No. (%) 0 (0.0) 0 (0.0) 1.00














Fig. 1. Comparison of operator’s satisfaction score between mid-
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group (9.1% in M group, 9.1% in MP group), while perforation 
did not occur in either group (Table 4).
DISCUSSION 
It was found that MP group was more satisfying than M gr-
oup by the endoscopist’s evaluation, which is explained by less 
patient movement and no significant difference in procedure 
duration and side effects, contributing to a better procedural 
environment for the endoscopist’s satisfaction. In case of M 
group, 45% of patients (10/22) could not achieve a sedative con-
dition until the maximum dose of 15 mg was administered and 
had to be switched to propofol, which might have most affect-
ed the endoscopist’s satisfaction. Patients switched to propo-
fol did not have serious side effects such as high blood pressure 
or apnea, but they required as much dose of propofol as MP gr-
oup, on top of the already maximum dose of midazolam.
Midazolam and propofol are currently the most commonly 
used sedatives for conscious sedation endoscope.
1 Midazol-
am has 2-3 times stronger sedative effect with less phlebitis 
compared to diazepam of the same benzodiazepine class, and 
induces anterograde amnesia effect.
2 Midazolam requires 
about 3 minutes after the IV administration before the seda-
tive effect starts and more than 1 hour until the effect is waned 
away, which is why 1-2 hours of observation by a medical team 
is required for recovery after the endoscopy.
3,4 Propofol which 
is popularly used for sedation during endoscopic examination 
has a chemical formula of 2,6-diisopropylphenol, comprised 
of 1% propofol, 10% bean oil, 2.25% glycerol, and 1.2% egg le-
cithin.
5 When administered intravenously, propofol could ra-
pidly pass the blood brain barrier and activates aminobutyric 
acid to induce sedation, amnesia, and sleeping. Sedative effects 
can occur within average 30-60 seconds after IV administra-
tion, and recover rapidly due to 1.3-1.4 minutes of short half-
life.
6 Various dosing is possible depending on the type and dur-
ation of procedure due to the short action time. Recommend-
ed loading dose for the first injection is 0.75-1.0 mg/kg and re-
peated administration is allowed at several minutes of interval.
7
Effectiveness of propofol is well established in various lit-
eratures. Carlsson and Grattidge
8 reported that propofol has 
better compliance and sedative effect than midazolam, more 
rapid recovery, and similar anterograde amnesia, arterial blo-
od oxygen saturation, and patient comfort as midazolam. Koo 
et al.
9 reported that low dose or high dose midazolam and pro-
pofol combination treatment induced similar sedative effect as 
high dose of midazolam single treatment, and there was no sig-
nificant difference in recovery time. Propofol was also more 
effective than midazolam for endoscopic retrograde cholan-
giopancreatography, which requires longer procedure time; 
midazolam and propofol combination treatment was not more 
effective than propofol single treatment, but fewer side effects 
were induced by decreasing the dose of propofol.
10 According 
to McClune et al.
11 combination of midazolam and propofol in-
duced synergy effect and the dose of propofol could be reduc-
ed. Reimann et al.
12 also reported that low dose midazolam 
and propofol combination treatment induced synergy effect 
in preparation for colonoscopy in patients 60 years old or less, 
and better comfort during the procedure and shorter recov-
ery time that midazolam and opioids combination treatment. 
These reports, combined with our study results, suggest that 
midazolam and propofol combination treatment could reduce 
the required dose of propofol, improves the patients’ comfort, 
and provides better environment for endoscopists.
Although propofol in our study was not different in its stabi-
lity between M group and MP group, it is generally known 
that propofol might increase the risk of hypotension, respira-
tion or heart rate suppression, or pain at the injection site. It is 
important, therefore, to reduce the dose of propofol and care-
fully monitor the vital sings in order to prevent side effects 
when propofol was used with other sedatives. The risk of side 
effects is increased in older age, and it is recommended to pro-
vide oxygen through nasal cavity during the procedure.
13 Rex 
et al.
14 performed a non-anesthesiologist administered pro-
pofol in 2,000 patients and reported that hypoxia of less than 
85% was occurred in 4 cases, all during endoscopy, which were 
soon recovered by using oxygen mask. Propofol was safely ad-
ministered by a skilled nurse under the supervision of an en-
doscopist. Cho et al.
15 performed gastrointestinal endoscopy 
using propofol in low risk group with ASA classific-ation I 
and II and high risk group of ASA classification III and IV, and 
found that high risk group experienced significantly increas-
ed incidence of hypoxia but a single case of apnea during the 
procedure. Oxygen saturation was reduced to 90% or less in 1 
patient at each group for a short period of time less than 10 se-
conds, but immediately returned to normal condition after 
using the oxygen mask.
The incidence of complication was relatively low, probably 
due to the exclusion of chronic patients with ASA III and IV, 
less older patients, and less dose of midazolam and propofol 
compared to other studies. The predictive factors of hypoxia 
include patient age, cardio pulmonary function before the pro-
cedure, obesity, rate of sedative administration, other diseases 
such as chronic obstructive pulmonary disease, and the expert-
ness of the endoscopist. Hypoxia is assumed to be caused by 
respiratory suppression by sedatives, aspiration, diaphragma-
tic hypokinesia, bronchoconstriction, or transient closure dur-
ing insertion of the endoscope.
16 In this study, propofol 20 mg 
was first administered as an inductive dose and then additio-
nal 20 mg was repeatedly injected according to the patient’s 
sedation. This dosage is equivalent to 1.13 mg/kg in ASA I pa-26  Clin Endosc 2011;44:22-26
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tient and 1.15 mg/kg in ASA II patients, and relatively less than 
propofol 2 mg/kg recommended by the Korean Society of 
Anesthesiologists.
17 Less dose of 1.0-1.75 mg/kg is recommend-
ed for patients of 60 years or older.
17,18 High dose of propofol 
more than 2.5 mg/kg induced significantly more side effects 
than standard dose, such as reduced blood pressure and pe-
ripheral artery oxygen saturation and increased pulse rate.
19 
Although not included in this study, injection site pain, one 
of the most common complications of propofol, is a contribut-
ing factor to decrease the patient satisfaction. Some reporters 
suggested that injecting 1% lidocaine of 1 cc to the vessel be-
fore propofol injection, injecting cold propofol of 0-4°C, or in-
jecting cool normal saline before sedation could be useful for 
pain relief.
20 
Both groups in this study reported good satisfaction at 1 
hour and at 24 hours after the ESD, and few patients complain-
ed discomfort on the next day. It was suggested that mida-
zolam and propofol combination treatment induced better 
sedation, based on the fact that less discomfort was reported 
both 1 hour and 24 hours after the ESD, compared to mid-
azolam single treatment.
This study has several limitations that the sample size was 
small, older and high risk patients of ASA III and IV were ex-
cluded, double-blind design was not applicable in the endos-
copist due to the different color of each sedative (midazolam 
is colorless transparent drug, while propofol is opaque white 
drug), which might have caused bias in the satisfaction of the 
endoscopist. The endoscopist’s subjective judgement might 
have involved in the evaluation of his satisfaction, since only 
one endoscopist participated in the study. Further studies are 
needed in patients with various age groups to review the effi-
cacy and stability of midazolam and propofol combination 
treatment. 
In conclusion, low dose midazolam and propofol combin-
ation treatment induces better sedative effect and endoscopist’s 
satisfaction compared to midazolam single treatment with si-
milar degree of complication and consciousness recovery as 
a sedation strategy for ESD.
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